Breaking News

Oracle is developing a national health records database

Not rendering correctly? View this email as a web page here.

StartUPDATES: New developments from healthcare startups

By Stephanie Baum Friday, June 10, 2022 7:47 AM

Check out news from Equiva, PrecisionGx, Wavemaker Three-Sixty Health, Jasper Health, and Anagenex.

Read more »

GSK immunotherapy shows promise as alternative to surgery in certain rectal cancers

By Frank Vinluan Thursday, June 9, 2022 7:15 PM

A small Memorial Sloan Kettering Cancer Center study found that all rectal cancer patients treated with GSK drug Jemperli showed a complete response at six months—there were no detectable signs of the cancer. These early data presented at ASCO suggest that rectal cancer with a particular genetic signature might be treatable with this immunotherapy in lieu of the standard regimen of chemotherapy, radiation, and surgery.

Read more »

State high court says Eli Lilly warned doctor of drug risks, didn't need to warn patient

By Amanda James Thursday, June 9, 2022 3:23 PM

Rejecting part of the decision, one justice said patients do not need a physician's knowledge to understand a drug company's warnings.

Read more »

Clinician burnout? Switch them to at-home care

By Katie Adams Thursday, June 9, 2022 1:48 PM

Hospital-at-home advocates often highlight how the care modality improves the patient experience and allows hospitals to better manage capacity. There are other key benefits — such as protecting patients from hospital-acquired infections and improving caregiver's job satisfaction — that should be brought into the conversation as well, hospital executives say.

Read more »

Roche bispecific drug Lunsumio lands European nod in follicular lymphoma

By Frank Vinluan Thursday, June 9, 2022 1:04 PM

Follicular lymphoma patients in Europe now have a new treatment option. The European Commission approved Roche drug Lunsumio, a bispecific antibody designed to go after two targets to treat advanced cases of this type of cancer.

Read more »

   

No comments